Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
4(66.7%)
Phase 2
2(33.3%)
6Total
Phase 1(4)
Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT03136809Phase 1Unknown

ALS Treatment Extension Study

Role: lead

NCT04313166Phase 2Completed

Treatment Continuation Study for Patients With ALS/MND Who Completed Study CMD-2019-001

Role: lead

NCT03204929Phase 1Completed

Dose Escalation Study of Cu(II)ATSM in Parkinson's Disease

Role: lead

NCT02870634Phase 1Completed

Phase 1 Dose Escalation and PK Study of Cu(II)ATSM in ALS/MND

Role: lead

NCT04082832Phase 2Unknown

CuATSM Compared With Placebo for Treatment of ALS/MND

Role: lead

NCT02688101Phase 1Completed

Dose-finding and Pharmacokinetic Study of DpC, Administered Orally to Patients With Advanced Solid Tumors

Role: lead

All 6 trials loaded